Investor Presentation Q1 2023

7 Investor presentation First three months of 2023 Novo NordiskⓇ International Operations diabetes care sales growth is driven by GLP-1 performance Reported Diabetes care sales and growth per IO geography GLP-1 patients and value market share in IO DKK billion Insulin I GLP-1 Growth at CER Number of patients (millions) Value market share Class growth ~50% 20 12% 6 75% 65.2% LO 5 60% 15 52% 19% Geographical regions 4 43.7% 45% 10 3 32.3% 30% 57% 17% 2 -8% -7% 5 40% 1 56% -5% -22% 4% 0 0 IO EMEA China ROW Feb-21 Feb-22 GLP-1 patients Ⓡ Rybelsus 12.8% 15% 8.7% 0% Feb-23 -OzempicⓇ ―dulaglutide IO: International Operations; NN: Novo Nordisk; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; Row: Rest of World; CER: Constant exchange rates Note that the market share and patient numbers are based on countries with IQVIA coverage. GLP-1 class growth calculated as Dec'22-Feb'23 vs Dec'21-Feb'22 (Rolling 3 month average) Source: IQVIA MAT, Feb 2023 (Spot rate). Volume packs are converted into full-year patients based on WHO assumptions for average daily doses -VictozaⓇ -NN GLP-1

View entire presentation